In 2013, Matsubaraet al [9] found that the frequency of TEMs, as defined as CD14+CD16+TIE2+ cells in peripheral blood, was significantly higher in HCC patients than that in non-HCC patients, and that the frequency changed with the therapeutic response or recurrence. This evidence concerns the gene TEK and hepatocellular carcinoma.